Ashley Gallagher is an assistant editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
Cognitive Tests Via Smartphone Help Identify Early Amyloid Changes Associated With Alzheimer Disease
January 4th 2024The pattern for the diminished learning curve, associated with elevated amyloid levels, was consistent across 3 memory tasks, with strongest results for recalling digit-signs and groceries prices.
Read More
No Difference Observed Between Branded, Biosimilar Enoxaparin for Post-Operative Thrombosis
January 4th 2024There was no statistically significant difference between Lovenox (Sanofi–Aventis Pharmaceuticals, France) and biosimilar enoxaparin in the occurrence of post-operative thrombosis for digestive cancer.
Read More
Statins Could Potentially Slow Deterioration of Cognitive Function for Those With Alzheimer Disease
January 4th 2024Due to the observational nature of the study, the study authors said they cannot determine causal relationships between statins and cognitive decline for patients with Alzheimer disease.
Read More
Investigational Vaccine Has Non-Inferior Immune Response Compared to PCV20 for Pneumococcal Disease
December 13th 2023Clinical trial results show the immunogenicity, tolerability, and safety of V116 compared to a pneumococcal 20-valent conjugate vaccine for adults who had not previously received a pneumococcal vaccine.
Read More
Tirzepatide Results in Superior Mean Percent Change in Body Weight for Those with Obesity
December 13th 2023In the phase 3 SURMOUNT-4 trial, investigators included individuals with at least 1 weight-related complication, including hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
Read More
Biosimilar Candidate GP40141 Found Similar to Romiplostim for Idiopathic Thrombocytopenic Purpura
December 1st 2023The aim of developing GP40141 as a biosimilar is to help reduce the cost of the drug and make treatment more affordable for those with idiopathic thrombocytopenic purpura, according to investigators.
Read More